Scott L. Burrows, Chief Financial Officer at Spyre Therapeutics, Inc. (SYRE), sold 25,000 shares at $89.89 ($2.3M) on 2026-09-30, disclosed to the SEC on 2026-10-02.
Scheduled sale ($2.3M) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $89.89 | 17,500 | $1.6M | 69.5% |
| 2 | $89.07 | 600 | $53K | 2.4% |
| 3 | $90.27 | 1,500 | $135K | 6.0% |
| 4 | $91.92 | 2,100 | $193K | 8.5% |
| 5 | $92.95 | 3,071 | $285K | 12.6% |
| 6 | $93.57 | 229 |
| $21K |
| 0.9% |
| Total | $90.47 avg | 25,000 | $2.3M | 100% |
| Filing → |
| SYRE | SELL | 2026-07-02 | $658K | — | Filing → |
| SYRE | SELL | 2026-06-26 | $1.3M | — | Filing → |
| SYRE | SELL | 2026-06-03 | $533K | — | Filing → |